Kurtuluş AKSU, Funda AKSU

Astım tedavisinde montelukastın yeri nedir?

Astım tüm dünyada en yaygın kronik hastalıklardan biri olup, inhale glukokortikosteroidler astım tedavisinde en etkin, dolayısıyla ilk seçenek tedavi yöntemidir. Tedavide ilk seçenek olmayan antilökotrienlerin, inhale glukokortikosteroidlere uyum sorunu olan veya inhaler tekniği doğru uygulayamayan hastalarda birinci basamak kontrol edici ajan olarak kullanılmaları mantıklıdır.

What is the role of montelukast in asthma treatment?

Asthma is a common chronic pulmonary disease worldwide. Inhaled glucocorticoids are the most effective therapeutic agents in treatment of asthma and are therefore the first drug of choice in asthma treatment. Antileukotrienes are alternative controller drugs in management of asthma especially in patients who cannot use inhaled glucocorticoids effectively due to compliance problems or poor inhaler techniques.

PDF

___

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Erişim tarihi: 29 Haziran 2020. Available from: www.ginasthma.org
2. Cabieses B, Uphoff E, Pinart M, Antó JM, Wright J. A systematic review on the development of asthma and allergic diseases in relation to international immigration: the leading role of the environment confirmed. PLoSOne. 2014; 9(8): e105347.
3. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet 2018; 391(10122): 783-800.
4. Kurt E, Metintas S, Basyigit I, Bulut I, Coskun E, Dabak S, et al. Prevalence and risk factors of allergies in Turkey (PARFAIT): results of a multicentre cross-sectional study in adults. Eur Respir J 2009; 33(4): 724-33.
5. Peters-Golden M, Henderson Jr WR. Leukotrienes. N Engl J Med 2007; 357(18): 1841-54.
6. Drazen JM, O’Brien J, Sparrow D, Weiss ST, Martins MA, Israel E, et al. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992; 146(1): 104-8.
7. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166(3): 301-6.
8. Reiss TF, Hill JB, Harman E, Zhang J, Tanaka WK, Bronsky E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52(12): 1030-5.
9. Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med 2015; 163(10): 756-67.
10. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158(11): 1213-20.
11. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171(4): 315-22.
12. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotrienereceptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108(3): e48.
13. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012; 2012(5): CD002314.
14. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014: 43(2): 343-73.
15. Mc Quaid EL, Kopel SJ, Klein RB, Fritz GK. Medication adherence in pediatric asthma: reasoning, responsibility, and behavior. J Pediatr Psychol 2003; 28(5): 323-33.
16. Aksu F, Şahin AD, Şengezer T, Aksu K. Effect of trainingby a physician on dynamics of theuse of inhaler devices to improve technique in patients with obstructive lung diseases. Allergy Asthma Proc 2016; 37(5): 98-102.
17. Maspero JF, Dueñas-Meza E, Volovitz B, Pinacho Daza C, Kosa L, Vrijens F, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001; 17(2): 96-104.
18. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legorreta AP. Adherence to asthma controller medication regimens. Respir Med 2005; 99(10): 1263-7.
19. Bukstein DA, Luskin AT, Bernstein A. “Real-world” effectiveness of Daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003; 90(5): 543-9.
20. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364(18): 1695-707.
21. Virchow JC, Mehta A, Ljungblad L, Mitfessel H, MONICA study group. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-labelstudy: the MONtelukast in chronic asthma (MONICA) study. Respir Med 2010; 104(5): 644-51.
22. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58(3): 211-6.
23. Ye YM, Kim SH, Hur GY, Kim JH, Park JW, Shim JJ, et al. Addition of montelukast to low-dose inhaled corticosteroid leads to fewer exacerbations in older patients than medium-dose inhaled corticosteroid monotherapy. Allergy Asthma Immunol Res 2015; 7(5): 440-8.
24. Löfdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319(7202): 87-90.
25. Riccioni G, Vecchia RD, Castronuovo M, DiIlio C, D’Orazio N. Tapering dose of inhaled budesonide in subjects with mild-to-moderate persistent asthma treated with montelukast: a 16-week single-blindrandomizedstudy. Ann Clin Lab Sci 2005; 35(3): 285-9.
26. Tohda Y, Fujimura M, Taniguchi H, Takagi K, Igarashi T, Yasuhara H, et al. Leukotrienereceptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin Exp Allergy 2002; 32(8): 1180-6.